The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding.
Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) — The “Cancer Vaccine Market – A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.
The global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted therapies.
Growth in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer vaccines.
The increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy’s success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic malignancies.
Regional market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities.
The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer care.
Despite positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability concerns.
The competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline development.
Looking ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines.
2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-2035 2.1 Preventive Vaccines 2.1.1 Gardasil 2.1.2 HEPLISAV-B 2.2 Therapeutic Vaccines 2.2.1 Bacillus Calmette-Guerin (BCG) 2.2.2 Sipuleucel-T (Provenge)
3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-2035 3.1 Recombinant 3.2 Cell-based 3.3 Others
4. Global Cancer Vaccine Market, by Region, $Million, 2023-2035 4.1 North America 4.1.1 Market Dynamics 4.1.2 Market Sizing and Forecast 4.1.3 North America Cancer Vaccine Market, by Country 4.1.3.1 U.S. 4.2 Europe 4.2.1 Market Dynamics 4.2.2 Market Sizing and Forecast 4.2.3 Europe Cancer Vaccine Market, by Country 4.2.3.1 U.K. 4.2.3.2 France 4.2.3.3 Germany 4.2.3.4 Italy 4.2.3.5 Spain 4.3 Asia-Pacific 4.3.1 Market Dynamics 4.3.2 Market Sizing and Forecast 4.3.3 Asia-Pacific Cancer Vaccine Market, by Country 4.3.3.1 Japan
5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles 5.1 Competitive Landscape 5.1.1 Mergers and Acquisitions 5.1.2 Partnership, Alliances and Business Expansion 5.1.3 New Offerings 5.1.4 Regulatory Activities 5.1.5 Funding Activities 5.2 Company Profiles 5.2.1 Overview 5.2.2 Top Products / Product Portfolio 5.2.3 Top Competitors 5.2.4 Target Customers/End-Users 5.2.5 Key Personnel 5.2.6 Analyst View
Merck & Co., Inc.,
Dynavax Technologies Corporation
Dendreon Pharmaceuticals LLC
Moderna, Inc
BioNTech SE
Transgene S.A.
Imugene Limited
Ose-Immuno
Barinthus Biotherapeutics
For more information about this report visit https://www.researchandmarkets.com/r/wf67a8
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
